Arturo M. Molina
Chief Medical OfficerDr. Arturo M. Molina is Member of Clinical Advisory Board of Rondo Therapeutics, Inc. from June 2024. He has been the Chief Medical Officer at Protagonist Therapeutics, Inc. since November 2022. Dr. Molina served as an Independent Director at Forma Therapeutics Holdings, Inc. from January 2022 to October 14, 2022 and serves as Board Member at Forma Therapeutics, Inc. He had been the Chief Medical Officer at Sutro Biopharma, Inc. from February 2016 to November 04, 2022. Dr. Molina has therapeutic program development experience. Dr. Molina has led scientific innovation and driven clinical programs forward. With his extensive experience interacting with the FDA and other global regulatory bodies, he has led the development of hematological and oncologic clinical candidates from phase I through phase III and through post-marking trials. While working for Johnson & Johnson, Dr. Molina oversaw the approval of Zytiga® in a multitude of countries for metastatic castration resistant prostate cancer indications. Previously, Dr. Molina served as Executive Vice President of Clinical Research & Development and Chief Medical Officer at Cougar Biotechnology, Inc. since August 2008 and also served as its Senior Vice President of Clinical Research and Development since May 2007, where his leadership efforts advanced its abiraterone program, Zytiga®, from phase I into several global phase III studies. Dr. Molina has also held leadership positions at Biogen Idec, where he led hematology/oncology clinical development and oversaw the post-approval label expansion of Rituxan®. Prior to Biogen Idec, Dr. Molina was a Faculty Staff Physician in the Department of Hematology/Bone Marrow Transplantation and Department of Medical Oncology/Therapeutics Research at City of Hope Comprehensive Cancer Center and Adjunct Professor from 2004 to 2007. Dr. Molina served on the Board of Directors of City of Hope Medical Group. He is an Oncologist. He served as Vice President of Oncology Scientific Innovation at Johnson & Johnson's California Innovation Center, an organization focused on building early stage collaborations with emerging companies from February 2013 to February 2016. Dr. Molina served as Chief Medical Officer and Vice President of Clinical Development for Johnson and Johnson's Ortho Biotech Oncology Research and Development, a unit of Cougar Biotechnology, Inc. He served as Chief Medical Officer of Cougar Biotechnology, Inc., Senior Director and Interim Head of Oncology and Hematology in the Department of Medical Research and Clinical Development at Biogen Idec, Inc. and Senior Director of Medical Affairs at IDEC Pharmaceuticals Corporation. He is board certified in internal medicine and medical oncology and has an active California medical license. He completed his post-graduate residency training in Internal Medicine and fellowships in Medical Oncology, Biological Sciences and Bone Marrow Transplantation at Stanford. Dr. Molina is an internationally acclaimed clinician, hematology and oncology researcher, practicing physician and pioneer for change in healthcare inequities. Dr. Molina is also an Adjunct Clinical Associate Professor at the Stanford School of Medicine, Oncology Division. Dr. Molina received an MS in Physiology and MD from Stanford University School of Medicine. Dr. Molina received a B.S. in Zoology and B.A. in Psychology from the University of Texas at Austin.
Positions
- Company NameProtagonist Therapeutics, Inc.Stock CodePTGXPositionChief Medical OfficerColleagues
- DVDinesh V. PatelCEO, President, Secretary & Director
- HEHarold E. SelickIndependent Chairman
- AAAsif AliExecutive VP & CFO
- VTVenkat ThalladiEVP & Chief Technical Officer
- NYNewman YeildingExecutive VP, Chief Scientific Officer
- CSChaitan S. KhoslaChairman of Scientific Advisory Board
- WDWilliam D. WaddillIndependent Director
- BGBryan GiraudoIndependent Director
